Skip to main content

Table 4 Comparison of subjects with and without colistin-resistant E. coli or K. pneumoniae colonization after study enrollment among subjects without colonization with colistin-resistant E. coli or K. pneumoniae at study enrollment

From: Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Variables

Colonization after enrollment (n = 42)

No Colonization after enrollment (n = 73)

p-value

Female gender (yrs), n (%)

20 (47.6%)

37 (50.7%)

0.75

Age (yrs), mean ± SD

66.6 ± 15.6

68.5 ± 15.1

0.54

ICU admission, n (%)

15 (35.7%)

24 (32.9%)

0.76

Previous hospitalization, n (%)

21 (50.0%)

37 (50.7%)

0.94

APACHE II score at study enrollment, mean ± SD

21.8 ± 7.2

21.9 ± 7.6

0.92

Mechanical ventilation, n (%)

39 (92.9%)

58 (79.5%)

0.06

Indwelling central venous catheter, n (%)

28 (66.7%)

40 (54.8%)

0.21

Surgery, n (%)

26 (61.9%)

39 (53.4%)

0.38

Chronic intermittent hemodialysis, n (%)

4 (9.5%)

10 (13.7%)

0.51

Antibiotic use for current hospitalization prior to study enrollment and during study period, n (%)

 Carbapenems

35 (83.3%)

66 (90.4%)

0.26

 Cephalosporins

20 (47.6%)

31 (42.5%)

0.59

 Beta-lactam/beta-lactamase inhibitors

33 (78.6%)

52 (71.2%)

0.39

 Fluoroquinolones

25 (59.5%)

33 (45.2%)

0.14

 Vancomycin

23 (54.8%)

38 (52.1%)

0.78

 Aminoglycosides

5 (11.9%)

2 (2.7%)

0.10

Antibiotic use for the current hospitalization after study enrollment, n (%)

 Carbapenems

19 (45.2%)

34 (46.6%)

0.89

 Cephalosporins

6 (14.3%)

4 (5.5%)

0.17

 Beta-lactam/beta-lactamase inhibitors

25 (59.5%)

36 (49.3%)

0.29

 Fluoroquinolones

19 (45.2%)

25 (34.2%)

0.24

 Vancomycin

17 (40.5%)

27 (37.0%)

0.71

 Aminoglycosides

4 (9.5%)

2 (2.7%)

0.19

Colistin use within 3 months prior to study enrollment, n (%)

9 (21.4%)

2 (2.7%)

0.002

Total amount of colistin (mg), median (range)

2800 (400–9350)

2000 (300–10,650)

0.03

Total duration of colistin use (days), median (range)

13 (2–55)

9 (1–32)

0.03

Total courses of colistin therapy, mean ± SD

1.3 ± 0.6

1.1 ± 0.34

0.02

Total courses of colistin therapy, range

1–3

1–3

 

Patients who received more than 1 course of colistin therapy, n (%)

10 (23.8%)

6 (8.2%)

0.02

Length of hospital stay (days), median (range)

46.5 (12–246)

32 (6–192)

0.04

All-cause mortality at hospital discharge, n (%)

35 (47.9%)

19 (45.2%)

0.78